Omicron variant and vaccines: Moderna and Pfizer are divided on efficacy

BERLIN – “In no case, I think, will we be able to count on the same effectiveness that we have experienced in the case of the Delta variant”. The cold shower arrived yesterday morning, from the columns of the Financial Times. The CEO of the drug giant Moderna, Stéphane Bancel, swept away in an interview with the financial newspaper the hope that existing vaccines could be an effective shield against Omicron, the latest coronavirus mutation that has reached Europe.